Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.

ABSTRACT:

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC9517939 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature